Stent thrombosis in patients treated with drug-eluting stents and bioresorbable vascular scaffolds:Mechanisms, long-term outcomes and sex differences

Historically, the occurrence of stent thrombosis has been the Achilles heel of percutaneous coronary intervention (PCI). Stent technology, implantation technique, and adjunct pharmacological therapy have been constantly adjusted to reduce the risk of stent thrombosis. The aim of the current thesis was to evaluate the impact of stent thrombosis and identify its predictors in the current era of PCI. Part II depicts the long-term safety of novel coronary devices. Part III evaluates the impact of sex on clinical outcomes after PCI. In the current PCI era, the prognosis of stent thrombosis is still unfavorable with high mortality risk. But also the risk of bleeding, the counterpart of thrombosis, must be emphasized for each individual patient undergoing PCI. Namely, both bleeding and thrombosis after PCI significantly influence the mortality risk. The absorb bioresorbable vascular scaffold is associated with a higher scaffold thrombosis risk. This risk continues up to four years post implantation. The COMBO stent uses anti-CD34+ antibodies to enhance functional healing of the vessel wall. This technique may have led to the low rate of stent thrombosis during long-term follow-up. Stent thrombosis rates were numerically lower for both the absorb as the COMBO stent in females compared to males. Another study demonstrated a similar risk death or myocardial infarction between the sexes. In contrast, the risk of major bleeding was higher in females compared to males

The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy

It has been hypothesized that dedicated optimized Absorb BVS implantation techniques might mitigate the risk of adverse events such as target vessel